Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia
Status:
COMPLETED
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
Dextromethorphan acts as N-methyl-D-aspartate (NMDA) antagonist. In Treatment resistant schizophrenia(TRS) the efficacy of treatment response by clozapine is only around 40%. Numerous augmentation agent have been tried which includes antipsychotics, anticonvulsants, antidepressants and NMDA antagonist. The NMDA antagonist such as Riluzole and Memantine have shown good efficacy in TRS. Therefore we are evaluating NMDA antagonist, dextromethorphan in TRS. The dextromethorphan or placebo will be administered along with clozapine in TRS patients. The study is randomized double blind placebo controlled group sequential trial.
Phase:
PHASE4
Details
Lead Sponsor:
All India Institute of Medical Sciences, Bhubaneswar